The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction
Authors:
Open Access
- 11 July 2017
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 16 (1) , 1-11
Abstract
Previous studies regarding the cardioprotective effects of dipeptidyl peptidase 4 (DPP-4) inhibitors have not provided sufficient evidence of a relationship between DPP-4 inhibition and actual cardiovascular outcomes. This study aimed to evaluate the impact of DPP-4 inhibitors on the survival of diabetic patients after first acute myocardial infarction (AMI). This was a nationwide, propensity score-matched, case–control study of 186,112 first AMI patients, 72,924 of whom had diabetes. A propensity score, one-to-one matching technique was used to match 2672 controls to 2672 patients in the DPP-4 inhibitor group for analysis. Controls were matched based on gender, age, and a history of hypertension, dyslipidemia, diabetes, peripheral vascular disease, heart failure, cerebrovascular accident, end-stage renal disease, chronic obstructive pulmonary disease, and percutaneous coronary intervention. DPP-4 inhibitors improve the overall 3-year survival rate (log rank P < 0.0001), whether male or female. Cox proportional hazard regression showed DPP-4 inhibitor is beneficial in diabetes patients after AMI (HR = 0.86; 95% CI 0.78–0.95), especially in those patients with hypertension (HR = 0.87; 95% CI 0.78–0.97; P = 0.0103) and cerebrovascular disease (HR = 0.83; 95% CI 0.72–0.97; P = 0.018), but without dyslipidemia (HR = 0.78; 95% CI 0.67–0.92; P = 0.0029), without peripheral vascular disease (HR = 0.86; 95% CI 0.78–0.96; P = 0.0047), without heart failure (HR = 0.84; 95% CI 0.73–0.96; P = 0.0106), without end stage renal disease (HR = 0.86; 95% CI 0.77–0.95; P = 0.0035), and without chronic obstructive pulmonary disease (HR = 0.87; 95% CI 0.78–0.97; P = 0.0096). DPP-4 inhibitor therapy improved long-term survival in diabetic patients after first AMI, regardless of gender.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (Most 105-2314-B-075B-006, Most 105-2314-B-075B-007)
- Kaohsiung Veterans General Hospital (VGHKS 106-084, VGHKS 106-D01-3)
This publication has 43 references indexed in Scilit:
- DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathwayActa Diabetologica, 2013
- Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent mannerCardiovascular Diabetology, 2013
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesNew England Journal of Medicine, 2013
- DPP‐4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental DiabetesCardiovascular Therapeutics, 2013
- All‐cause mortality and cardiovascular effects associated with the DPP‐IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish populationDiabetes, Obesity and Metabolism, 2013
- Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia–reperfusion injuryInternational Journal of Cardiology, 2013
- Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical OutcomesPostgraduate Medicine, 2013
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trialsCurrent Medical Research and Opinion, 2011
- DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient MiceJournal of Cardiovascular Pharmacology, 2011